SRSD-107
- Generic Name
- SRSD-107
Tourmaline Bio's Heart Disease Antibody Shows Promise in Phase 2, But Shares Fall Amid Competition Concerns
• Tourmaline Bio's antibody drug pacibekitug demonstrated significant reduction in cardiovascular risk biomarkers compared to placebo in Phase 2 trials, but shares fell 18% as investors question its competitive edge against Novo Nordisk's offering.
• Schrödinger announced CFO Geoffrey Porges will leave the company amid near-record low share prices, coinciding with plans to lay off 7% of staff as part of cost-cutting measures.
• CRISPR Therapeutics is expanding its technological capabilities through a $95 million deal with Sirius Therapeutics to develop SRSD107, a novel siRNA blood thinner designed to minimize bleeding risk.
CRISPR Therapeutics Expands into siRNA Therapies with $95M Sirius Partnership for Thromboembolic Disorders
• CRISPR Therapeutics is diversifying beyond gene editing through a strategic $95 million partnership with Sirius Therapeutics to develop SRSD107, a long-acting siRNA therapy targeting Factor XI for thromboembolic disorders.
• In Phase 1 trials, SRSD107 demonstrated impressive efficacy with over 93% reduction in Factor XI levels and doubled blood clotting time, with effects lasting up to six months from a single dose.
• The collaboration includes a 50-50 cost and profit-sharing structure for SRSD107 development, with CRISPR leading U.S. commercialization and retaining rights to license two additional siRNA targets.
China Approves Remegen's Disitamab Vedotin for HER2-Positive Advanced Breast Cancer with Liver Metastasis
• China's National Medical Products Administration (NMPA) has approved Remegen's antibody-drug conjugate disitamab vedotin (RC-48) for patients with HER2-positive advanced breast cancer with liver metastasis.
• The approval marks a significant advancement in targeted therapy options for Chinese patients with advanced breast cancer, particularly addressing the challenging subset with liver metastases.
• Disitamab vedotin joins the growing field of antibody-drug conjugates targeting HER2, offering a new treatment approach in a market where targeted therapies for metastatic breast cancer remain an area of high unmet need.
Sirius Therapeutics Secures $50 Million in Series B2 Funding to Advance siRNA Therapies for Cardiometabolic Diseases
• Sirius Therapeutics has completed a nearly $50 million Series B2 financing round led by a corporate venture capital firm, with participation from new investor BioTrack Capital and existing investors.
• The funding will accelerate clinical development of the company's siRNA therapeutics for cardiometabolic disorders, including SRSD107, which is poised to begin Phase 2 trials in Europe for thromboembolic disorders.
• Since its founding in 2021, Sirius has established innovation centers in the US and China, advanced three programs to clinical stage, and raised approximately $150 million in total funding.
Sirus Therapeutics' SRSD107 Shows Promise in Phase I siRNA Trial for Thromboembolic Disorders
• Sirus Therapeutics' SRSD107 demonstrated safety and tolerability in a Phase I trial, marking a significant step in its development for thromboembolic disorders.
• The trial data revealed substantial reductions in Factor XI antigen and activity, exceeding 90% at the highest doses, indicating potent anticoagulation effects.
• SRSD107 exhibited durable pharmacodynamic effects, with activity levels remaining suppressed for over 16 weeks post-dosing, supporting its potential for twice-yearly administration.
• These positive results pave the way for Sirus Therapeutics to advance SRSD107 into Phase II clinical studies, further evaluating its efficacy in preventing and treating thrombosis.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath